Boku N et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. ESMO 2020;Abstract LBA7_PR.
Catenacci DVT et al. Margetuximab plus pembrolizumab for previously treated, HER2-positive GEA (CP-MGAH22–05): A single-arm, phase 1b-2 trial. Lancet Oncol 2020;21(8):1066-76. Abstract
Chin K et al. Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy. ASCO Gastrointestinal Cancers Symposium 2021;Abstract 204.
Janjigian YY et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial. Lancet Oncol 2020;21(6):821-31. Abstract
Kato K et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. ESMO 2020;Abstract LBA8_PR.
Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. ESMO 2020;Abstract LBA9_PR.
Lee MS et al. Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma. AACR 2021;Abstract CT174.
Lorenzen S et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS study of the AIO. ASCO 2020;Abstract 4514.
Moehler M et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. ESMO 2020;Abstract LBA6_PR.
Powell CA et al. Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. AACR 2021;Abstract CT167.
Shitara K et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382(25):2419-30. Abstract
Strickler JH et al. MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma — Trial in progress. ASCO Gastrointestinal Cancers Symposium 2021;Abstract TPS252.
Tabernero J et al. Trifluridine/tipiracil outcomes in third or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analysis from the TAGS study. ASCO Gastrointestinal Cancers Symposium 2021;Abstract 229.
Wainberg ZA et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). ASCO Gastrointestinal Cancers Symposium 2021;Abstract 160.
Xu R et al. Rainbow-Asia: A randomized, multicenter, double- blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine. ASCO Gastrointestinal Cancers Symposium 2021;Abstract 199.